Healthcare giant Johnson & Johnson (NYSE: JNJ )
continues to prosper by virtue of its strong pharmaceutical business
as the consumer and device business continue to languish. Not only does
Johnson & Johnson offer a strong internal pipeline that can help
maintain that momentum, the company has more than enough liquidity to
acquire/license drugs if it should want to go that route. A real
turnaround in devices appears to be a ways off, though, and these shares
don't scream "bargain" in the meantime.
Read the full article here:
Johnson & Johnson Ups The Dosage
No comments:
Post a Comment